Antiproliferative treatment of patients with metastatic endocrine gastroenteropancreatic tumours (GEP) is based mainly on chemotherapeutic protocols whereby drug toxicity is a major handicap. Octreotide is the first choice in the control of hormone mediated symptoms.
Abstract
Antiproliferative treatment of patients with metastatic endocrine gastroenteropancreatic tumours (GEP) is based mainly on chemotherapeutic protocols whereby drug toxicity is a major handicap. Octreotide is the first choice in the control of hormone mediated symptoms. From retrospective and a few prospective studies it has been suggested that octreotide exhibits antiproliferative properties. The In patients with metastatic endocrine gastroenteropancreatic (GEP) tumours definite healing of the disease cannot be achieved by the currently available therapeutic strategies. In the treatment of patients with metastatic GEP tumours, however, it is important to note that even in fast growing tumours control of hormone mediated symptoms improves or, at least normalises, the quality of life. 1-6 Spontaneous tumour growth varies from one patient to another with tumours and metastases remaining unchanged in size for months or even years without treatment, tumours growing slowly and independently on any antiproliferative measures, and tumours showing explosive growth.7 Aggressive antiproliferative strategies are only desired in the last of these tumours and in patients whose severity of associated endocrine syndrome is unresponsive to less harmful therapeutic measures. In principle, antiproliferative strategies include surgical tumour debulking,8 hepatic artery embolisation,9 10 chemotherapyll-16 and, in selected patients with liver metastases, liver transplantation.'7 Recently, a multicentre trial has presented encouraging results from patients with metastatic islet cell carcinoma responsive to the combination of streptozotocin and doxorubicin in terms of the rate of tumour regression, the length of time to subsequent tumour progression, and survival if compared with the standard regimen of streptozotocin plus fluorouracil.'6 Toxic reactions, however, including severe bone marrow suppression, nephrotoxicity, and heart failure have been seen in a substantial percentage of these patients. '6 In contrast, anaplastic neuroendocrine carcinomas, an entity characterised histologically by a less well developed neuroendocrine pattern and greater mitotic activity, explosive tumour growth, and less frequent clinically recognisable excess hormone production'8 responded well in a significant percentage to the combination of etoposide and cisplatin, whereas patients with well differentiated carcinoid tumours did not.'5 Again, drug toxicity was an important problem in this study. These studies clearly show, however, that subgroups of patients with metastatic endocrine GEP tumours may benefit from specific chemotherapeutic protocols whereas other subgroups fail. Therefore, alternative therapeutic strategies would be greatly desired particularly if they prove to be less compromising to the patient's quality of life compared with systemic chemotherapy.
Currently, interferon alpha,19-21 longacting somatostatin analogues, 7 22 23 and combina- tions2426 are under investigation with respect to their antiproliferative potencies, but because of the low incidence of the disease available data are based on small numbers of patients. The longacting somatostatin analogue octreotide is currently the therapeutic principle of first choice to control reliably flushing, wheezing, and diarrhoea in patients with carcinoid syndrome,6 27 Evaluation of response Follow up investigations were performed in three month intervals for one year and included physical examination, complete blood count, biochemical screening profile, hormones, and assessment of tumour growth as during pretreatment examination. For evaluation of clinical symptoms each patient kept a diary regarding number, extent and severity of flushing, frequency and consistency of bowel movements, and grading of their well being. In patients responding to treatment with growth inhibition follow up visits were extended to six month intervals after the first year.
Tumour growth was assessed by computed tomography of pertinent indicator lesions in a blind fashion without knowledge of the clinical data. Eighty nine of 103 patients had measurable disease in the liver. Number of metastases within the liver, ligament hepatoduodenale, mesenterium, periaortic lymphnodes or elsewhere was estimated as well as the size of two to three reference metastases and of an unresectable primary determined by measuring the respective perpendicular diameters. Planimetry during ultrasound and volumetry of computed tomography confirmed reference metastases was performed if possible. In seven patients the liver parenchyma was diffusely infiltrated by the tumour. Therefore, other criteria such as total liver size and newly developed ascites indicating peritoneal carcinosis seen in two patients with intestinal carcinoids have been used for follow up investigations.
In the study protocol progression was defined as an increase in tumour growth by more than 25% within three months assessed by multiplication of the length of two perpendicular diameters estimated in at least two different metastases or by the appearance of new metastases. Tumours growing slowly but continuously with progression of less than 25% within three months were also judged as 'progression' if progression of more than 25% occurred within the observation period of 12 months.
Stable disease was assumed if increase or decrease in tumour size of less than 25% was seen within the observation period.
Partial regression was defined as decrease in tumour size by more than 50% within the observation period.
Response to octreotide was defined as stable disease or decrease in tumour growth after confirmed progression before treatment or decrease in tumour growth after stable disease within the pretreatment period, if lasting for at least three months.
No assessment was possible if growth behaviour before octreotide was unknown, but showed stable disease during octreotide treatment. All patients with progression of tumour growth during octreotide treatment were considered as non-responders. Escape from initially successful treatment was defined as progression of tumour growth after ascertained response to octreotide for at least three months.
In terms of the hormonal assay, response to octreotide was defined as a decrease of at least 50% compared with pretreatment values and a duration of response for at least three months. Non-responders were those with less than 50% improvement and a duration of response for less than three months. Results A total of 122 of 167 registration forms were returned to the study office. The difference resulted from doctors deciding against treatment with octreotide and from patients refusing to participate in the trial mainly because of the need of three daily self injections. As judged by the participating centres 87 of 122 patients showed computed tomography confirmed tumour progression and 37 patients have been included in the trial because of the severity of the associated endocrine syndrome. Stable disease not requiring antiproliferative treatment has been reported in five patients. As random review of computed tomography performed at our institution showed discrepancies with the statements of participating hospitals concerning tumour progression before treatment every tomogram of patients included into the study was re-evaluated at our institution. This evaluation was performed by a radiologist not aware of the response criteria formulated in the study protocol. Participating hospitals were, therefore, asked to send tomogram copies to the study office. As Fig 1 shows , confirmed tumour progression was confirmed only in 52 patients, stable disease over six months was diagnosed in 13 patients whereas no confirmed preobservation period was assessed in 38 patients mainly because of poor computed tomography. The last two groups of patients were not excluded from further follow up as subsequent tomograms could satisfactorily be evaluated. Nineteen patients have been excluded from further follow up because of poor records in 14 and stable disease according to the decision of the participating hospitals in five patients. Therefore, the final study sample consisted of 103: fifty two patients with confirmed tumour progression, 13 patients with confirmed stable disease before onset of octreotide therapy, and 38 patients with no information on pre-entry tumour growth available. Tables I and II summarise patients' characteristics and the distribution of functional and non-functional tumours within the three subgroups according to tumour growth before start of octreotide treatment. Consistent with Figure 2 shows the length of time from stable disease to tumour progression in these 19 patients. After 12 months stable disease continued in 12 patients, declined after 24 months to nine patients, and after 36 months to five patients. The median duration of stable disease was 18 months.
As the results of the study depended on the evaluation of response, we studied in this subgroup the association of tumour growth inhibition and specific characteristics of patients' tumours (Table VI) . Patients with a good Karnofsky performance score responded significantly better to octreotide than those with a low performance score. There was no strong evidence that any other specific characteristic made a patient more responsive or resistant to octreotide treatment. Although the numbers were small, there was a tendency of endocrine tumours originating from the small intestine and of patients with carcinoid syndrome to respond better to octreotide treatment compared with pancreatic endocrine tumours and non-functional tumours. The ability of octreotide to improve flushing and diarrhoea in patients with carcinoid syndrome or to suppress hormone release failed to predict tumour growth inhibition.
In 13 patients stable disease for at least three months before octreotide was confirmed by computed tomography. None of these patients died during octreotide treatment and follow up for 12 months. Also in this subgroup no patient experienced tumour regression (Table VII) . After three months of treatment stable disease continued in 10 (76.9%) and after 12 months in seven (53-8%) patients. No evaluation was possible in three patients because of unsatisfactory computed tomography in two patients and discontinuation of treatment during the first month in one patient.
Therefore, according to the study protocol no patient within this subgroup responded to octreotide with respect to inhibition of tumour growth. Unfortunately, no usable information on spontaneous tumour growth before treatment was available in 38 patients. Also in this subgroup tumour regression did not occur during octreotide treatment (Table VIII) . During the observation period of 12 months, 10 patients (26.3%) died, whereas in 13 patients (34.2%) tumour progression and in 13 patients (3420/o) stable disease could be confirmed by serial computed tomography. Similar to the findings obtained from patients with stable disease before octreotide treatment most patients remained in tumour standstill up to month 12 if stable disease was seen at month 3 (Table VIII) . In one patient evaluation of response was not possible because of non-fatal unexplained septicaemia during the first two weeks of treatment and subsequent discontinuation of treatment.
In 28 patients with tumour progression during 200 pug octreotide thrice daily treatment dose was increased to 500 ,ug thrice daily: in 15 of 52 patients with tumour progression before octreotide, in three of 13 patients with stable disease, and in 10 of 38 patients with no information on spontaneous tumour growth before octreotide. Increase of octreotide dose to 500 pug thrice daily was performed in 11 patients at month 3, 12 patients at month 6, two patients at month 9, and three patients at month 12 for at least six subsequent months. In 27 patients increase of octreotide did not change tumour growth behaviour seen with the lower dose. Only in one patient with ongoing tumour progression at month 3 tumour standstill occurred lasting until the observation period of 12 months.
Toxicity
Octreotide was well tolerated. None Mortality within our study sample was considerably high and may reflect the Karnofsky performance score of 80 and below in 47 of 103 patients at study entry. Obviously, octreotide is unable to prevent fatal outcome in an advanced state of the disease.
We conclude that the results of this prospective phase II trial are strong enough to generate the hypothesis that octreotide inhibits tumour growth in patients with metastatic endocrine GEP tumours. Further randomised trials based on a more homogeneous group of tumours and with survival time as end point will be needed to prove this hypothesis, to identify those subgroups of tumours responding to octreotide with inhibition of tumour growth, and to examine even higher doses of octreotide. Although there is some information from patients with malignant neuroendocrine tumours taking octreotide doses exceeding 5 mg/daily45 46 
